Long-term management of chronic immune thrombocytopenic purpura in adults

0Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.

Abstract

Chronic immune thrombocytopenic purpura (ITP) is generally a more benign disease than previously thought. Currently it is recommended that only those patients with severe and/or symptomatic thrombocytopenia definitely require treatment. Additional factors, such as age, lifestyle, and uremia can also influence the hemorrhagic risk and should be carefully assessed before decision-making on the appropriate managemnt of patients with less severe forms of ITP. The recent introduction of new classes of therapeutic agents such as rituximab and the thrombopoietic growth factors has had a major impact on the management of ITP. Updated treatment guidelines have recently been made available but they are based largely on expert opinion rather than on high-quality clinical trial evidence. This structured review is focused on the management of adults with chronic ITP, including the use of new © 2010 Palau et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. classes of agents.

Cite

CITATION STYLE

APA

Palau, J., Jarque, I., & Sanz, M. A. (2011). Long-term management of chronic immune thrombocytopenic purpura in adults. American Journal of Clinical Hypnosis, 53(4), 305–311. https://doi.org/10.2147/IJGM.S4722

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free